AU2002332290A1 - Recombinant anti-osteopontin antibody and use thereof - Google Patents

Recombinant anti-osteopontin antibody and use thereof

Info

Publication number
AU2002332290A1
AU2002332290A1 AU2002332290A AU2002332290A AU2002332290A1 AU 2002332290 A1 AU2002332290 A1 AU 2002332290A1 AU 2002332290 A AU2002332290 A AU 2002332290A AU 2002332290 A AU2002332290 A AU 2002332290A AU 2002332290 A1 AU2002332290 A1 AU 2002332290A1
Authority
AU
Australia
Prior art keywords
recombinant anti
osteopontin antibody
osteopontin
antibody
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002332290A
Other versions
AU2002332290B2 (en
Inventor
Hirofumi HIGUCHIi
Shigeyuki Kon
Hiroaki Maeda
Toshihiro Nakashima
Yoshiyuki Tokieda
Masaharu Torikai
Toshimitsu Uede
Nobuchika Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Astellas Pharma Inc
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Astellas Pharma Inc filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Priority claimed from PCT/JP2002/009868 external-priority patent/WO2003027151A1/en
Publication of AU2002332290A1 publication Critical patent/AU2002332290A1/en
Assigned to ASTELLAS PHARMA INC., IMMUNO-BIOLOGICAL LABORATORIES CO., LTD. reassignment ASTELLAS PHARMA INC. Request for Assignment Assignors: FUJISAWA PHARMACEUTICAL CO., LTD, IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.
Assigned to JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, ASTELLAS PHARMA INC. reassignment JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE Request for Assignment Assignors: Immuno-Biological Laboratories Co; Ltd
Application granted granted Critical
Publication of AU2002332290B2 publication Critical patent/AU2002332290B2/en
Assigned to ASTELLAS PHARMA INC., JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE reassignment ASTELLAS PHARMA INC. Alteration of Name(s) in Register under S187 Assignors: ASTELLAS PHARMA INC., JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002332290A 2001-09-25 2002-09-25 Recombinant anti-osteopontin antibody and use thereof Ceased AU2002332290B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001290700 2001-09-25
JP2001-290700 2001-09-25
PCT/JP2002/009868 WO2003027151A1 (en) 2001-09-25 2002-09-25 Recombinant anti-osteopontin antibody and use thereof

Publications (2)

Publication Number Publication Date
AU2002332290A1 true AU2002332290A1 (en) 2003-06-26
AU2002332290B2 AU2002332290B2 (en) 2007-11-08

Family

ID=19112969

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002332290A Ceased AU2002332290B2 (en) 2001-09-25 2002-09-25 Recombinant anti-osteopontin antibody and use thereof

Country Status (16)

Country Link
US (1) US7241873B2 (en)
EP (1) EP1431310A4 (en)
JP (1) JPWO2003027151A1 (en)
KR (1) KR20040048899A (en)
CN (1) CN100352844C (en)
AU (1) AU2002332290B2 (en)
BR (1) BR0213078A (en)
CA (1) CA2461529A1 (en)
HK (1) HK1084127A1 (en)
HU (1) HUP0402049A3 (en)
MX (1) MXPA04002837A (en)
NO (1) NO20041225L (en)
NZ (1) NZ531818A (en)
PL (1) PL369446A1 (en)
RU (1) RU2305111C2 (en)
WO (1) WO2003027151A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100469793C (en) * 2001-04-05 2009-03-18 株式会社免疫生物研究所 Anti-osteopontin antibody and use thereof
BR0213078A (en) 2001-09-25 2004-11-23 Fujisawa Pharmaceutical Co Recombinant anti-osteopontin antibody and use
AU2003258127A1 (en) * 2002-08-06 2004-02-23 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
WO2004103403A1 (en) * 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. Immunocompetent cell activation inhibitor and use thereof
EP2369348A1 (en) * 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
CA2552425C (en) * 2004-02-27 2018-02-06 F. Hoffmann-La Roche Ag Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
DK1721162T3 (en) * 2004-02-27 2008-12-15 Hoffmann La Roche Method to assess rheumatoid arthritis by measuring anti-CCP and serum amyloid A
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2006116793A1 (en) * 2005-05-04 2006-11-09 Australian Stem Cell Centre Limited Selecting, culturing and creating lineage committed hematopoietic stem cells
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
BRPI0711229A2 (en) * 2006-05-31 2013-01-08 Astellas Pharma Inc humanized anti-human osteopontin antibody, polynucleotide, expression vector, host cell, method for producing a humanized anti-human osteopontin antibody, therapeutic drug, method for preventing or treating autoimmune disease, and use of humanized west anti-human antibody
EP2075258B1 (en) * 2006-10-26 2012-06-20 Gene Techno Science Co., Ltd. Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same
KR101436578B1 (en) 2007-03-30 2014-09-01 슈 생-쥐스땡 Methods of determinng the risk of developing scoliosis, methods of stratifying a subject having a scoliosis, methods for assessing the efficacy of a brace on a subject having a scoliosis, and kits therefor
KR100894265B1 (en) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 Injectable Bone Regeneration Gel containing Bone Formation Enhancing Peptide
US9040666B2 (en) * 2007-07-13 2015-05-26 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian IgG
CA2709305C (en) * 2007-12-13 2017-03-07 The Curators Of The University Of Missouri Compositions and methods for early pregnancy diagnosis
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP2239323A4 (en) * 2008-01-11 2012-05-23 Chemo Sero Therapeut Res Inst Humanized anti-human 9-integrin antibody
AU2009238897B2 (en) * 2008-04-24 2015-03-19 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
CA2722466A1 (en) * 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY31861A (en) * 2008-06-03 2010-01-05 Abbott Lab IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
WO2010006060A2 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
CA2753280C (en) 2009-02-23 2017-04-25 Gene Techno Science Co., Ltd. Anti-human .alpha.9 integrin antibody and use thereof
BRPI1012195A2 (en) * 2009-05-01 2018-04-24 Abbott Lab double variable domain immunoglobulins and their uses
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR101809761B1 (en) * 2009-09-24 2017-12-15 가부시키가이샤 진 테크노 사이언스 Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
TW201119676A (en) * 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
JP2013537415A (en) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY33707A (en) * 2010-11-04 2012-05-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CN103747801A (en) 2011-05-27 2014-04-23 卡罗生物制药股份有限公司 Anti-emr1 antibodies
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
NZ707641A (en) 2012-11-01 2016-09-30 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
TW201512219A (en) 2013-03-15 2015-04-01 Abbvie Inc Dual specific binding proteins directed against IL-1[beta] and/or IL-17
TW201623329A (en) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof
AU2015300080B2 (en) * 2014-08-06 2021-04-01 Mach5 Therapeutics, Inc. New anti-human Igbeta antibody
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
US10349259B2 (en) * 2016-09-23 2019-07-09 Apple Inc. Broadcasting a device state in a wireless communication network
EP4010369A4 (en) * 2019-08-09 2023-11-22 The Board of Trustees of the Leland Stanford Junior University Therapeutic antibodies against osteopontin
CN115558015B (en) * 2022-10-12 2024-01-19 生工生物工程（上海）股份有限公司 Method for purifying GST-tag-free target protein from product obtained after GST fusion protein cleavage and product

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US239400A (en) * 1881-03-29 Tobacco-fork
US125023A (en) * 1872-03-26 Improvement in sand dredging-machines
US1408113A (en) * 1921-01-28 1922-02-28 Mason Richard Colbert Well-measuring device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0690132T3 (en) 1993-03-11 2004-04-13 Chemo Sero Therapeut Res Inst Monoclonal anti-HIV antibody
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
EP0705842A2 (en) 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
US6686444B2 (en) 1996-08-22 2004-02-03 Children's Medical Center Corporation Osteopontin derived chemotactic peptides and methods of use
WO1998008379A1 (en) 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
WO1998056405A1 (en) 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
EP1003570A1 (en) 1997-08-15 2000-05-31 Children's Medical Center Corporation Osteopontin coated surfaces and methods of use
EP0921189B1 (en) * 1997-11-14 2005-01-12 Sankyo Company Limited Transgenic animal allergy models and methods for their use
US6414219B1 (en) * 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
MXPA01010403A (en) 1999-04-15 2004-09-10 Childrens Medical Center Osteopontin-derived chemotactic and inhibitory agents and uses therefor.
EP1175223A2 (en) 1999-04-15 2002-01-30 Children's Medical Center Corporation Methods and compositions for modulating an immune response
EP1269196B1 (en) * 2000-03-23 2007-11-21 Glaxo Group Limited Method of screening for inhibitors of osteopontin
WO2002032940A2 (en) 2000-10-18 2002-04-25 Children's Medical Center Corporation Osteopontin-coated surfaces and methods of use
CN100469793C (en) * 2001-04-05 2009-03-18 株式会社免疫生物研究所 Anti-osteopontin antibody and use thereof
US7384633B2 (en) 2001-07-19 2008-06-10 Judicial Foundation The Chemo-Sero-Therapeutic Res. Human type antihuman IgE receptor antibody and fragment
BR0213078A (en) 2001-09-25 2004-11-23 Fujisawa Pharmaceutical Co Recombinant anti-osteopontin antibody and use
CA2468020A1 (en) 2001-11-21 2003-06-05 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
CN103518888A (en) * 2013-10-14 2014-01-22 李民庆 Heart-nourishing tranquilizing tea formula

Similar Documents

Publication Publication Date Title
AU2002332290A1 (en) Recombinant anti-osteopontin antibody and use thereof
HK1084127A1 (en) Recombinant anti-osteopontin antibody and use thereof
AU2002244968A1 (en) Anti-osteopontin antibody and use thereof
EP1375518A4 (en) Anti-osteopontin antibody and use thereof
HUP0400284A3 (en) Recombinant tumor specific antibody and use thereof
AU2002251913A1 (en) Hybrid antibodies and uses thereof
AU2001236073A1 (en) Gene recombinant antibody and its fragment
IL223047A (en) Antibody comprising an fc region and uses thereof
HK1043798A1 (en) Recombinant il-18 antibodies and their use
HUP0501113A3 (en) Cripto blocking antibodies and uses thereof
AU2002220843A1 (en) Humanised antibodies and uses thereof
AU2002338015A1 (en) Human CDR-grafted antibodies and antibody fragments thereof
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
AUPR546801A0 (en) Recombinant antibodies
GB0122724D0 (en) Trx1 antibody and uses therefor
AU2002312373A1 (en) Structural and cytoskeleton-associated proteins
AU2002357934A1 (en) Humanized lactoferrin and uses thereof
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2002368225A1 (en) Viral interferon antagonists and uses therefor
AU2002338089A1 (en) Antibody and use thereof
EP1437367A4 (en) Antibody and use thereof
AU2002343516A1 (en) Structural and cytoskeleton-associated proteins
AU2002320621A1 (en) Structural and cytoskeleton-associated proteins
AU2002330299A1 (en) Antibody and use of the same
AU2002230154A1 (en) Antibody and utilization thereof